Tinzaparin vs. Fraxiparin Safety and Efficacy in Neurosurgery

Florian Wilhelmy* | Annika Hantsche | Michael Gaier | Johannes Kasper | Michael Karl Fehrenbach | Rene Oesemann | Jürgen Meixensberger | Dirk Lindner

1 University Hospital Leipzig, Department of Neurosurgery, 04103 Leipzig, Liebigstrasse 20
2 University Hospital Leipzig, Department of Anesthesiology and Intensive Care, 04103 Leipzig, Liebigstrasse 20

Running title:
Tinzaparin in Neurosurgical Practice

Corresponding author:
Florian Wilhelmy

University Hospital Leipzig, Department of Neurosurgery, 04103 Leipzig, Liebigstrasse 20

Telephone: 0049 341 9717521 | Fax: 0049 341 9717509

Email: florian.wilhelmy@medizin.uni-leipzig.de

Funding:
No funding was received.

Conflict of interest:
The authors declare no conflict of interest.

Authorship:

* Equally contributing first authors

Study design and data analysis: FW, JK, MF | Manuscript: FW; AH, DL, RO, JM | Data: AH, MG
Word count:

659

Number of figures and tables:

2 tables, no figures

Keywords:

Tinzaparin, African swine fever, heparin shortage, fraxiparin, neurosurgery, perioperative anticoagulation

Details:

I hereby confirm that the manuscript complies with all instructions to authors. The authorship requirements have been met and the final manuscript has been approved by all authors. This manuscript has not been published elsewhere and is not under consideration by another journal. We confirm adherence to ethical guidelines and that ethical approval was obtained from the IRB (see below). Conflict of interest statements for all authors have been included. We have followed the STROBE guidelines.
Abstract

Background

An outbreak of African swine fever (ASF) in China in 2020 has led to an unprecedented shortage of fraxiparin. Most patients, especially those kept in hospital for surgery, are currently treated with prophylactic anticoagulation (AC). In search of alternatives for fraxiparin, we found no sufficient data on alternatives for neurosurgical patients, such as tinzaparin of European origin. We compared fraxiparin and tinzaparin concerning adverse events (bleeding versus thromboembolic events) in neurosurgical patients.

Methods

Between 2012 and 2018, 517 neurosurgical patients with benign and malignant brain tumors as well as 297 patients with subarachnoid hemorrhage (SAH) were treated in the Department of Neurosurgery, University Hospital Leipzig receiving prophylactic anticoagulation within 48 hours. In 2015, prophylactic anticoagulation was switched from fraxiparin to tinzaparin throughout the university hospital. In a retrospective manner, the frequency and occurrence of adverse events (rebleeding and thromboembolic events) in connection with the substance used was analyzed. Statistical analysis was performed using Fisher’s exact test and the chi-squared test.

Results

Rebleeding rates were similar in both fraxiparin and tinzaparin cohorts in patients being treated for meningioma, glioma, and SAH combined (8.8 vs 10.3%). Accordingly, the rates of overall thromboembolic events were not significantly different (5.5% vs 4.3%). The severity of rebleeding did not vary. There was no significant difference among subgroups when compared for deep vein thrombosis (DVT) or pulmonary embolism (PE).

Conclusion

In this retrospective study, tinzaparin seems to be a safe alternative to fraxiparin for AC in patients undergoing brain tumor surgery or suffering from SAH.
Introduction

All hospitalized patients are currently treated with prophylactic anticoagulation (AC) according to guidelines [1, 2, 3]. (Neuro-)surgical patients are at elevated risk of both thromboembolic events and intracranial rebleeding [4, 5, 6]. Data on low molecular weight heparin (LMWH) safety is therefore essential for safe prophylactic treatment. Due to an outbreak of African Swine Fever (ASF) in China [7], heparin doses are at risk of running short. Many hospitals use LMWH of Chinese production. Should there be an actual shortage, alternatives are required to maintain supply. Quite recently, the first case of ASF in wildlife was discovered in Germany, indicating a westward movement of the disease [8, 9].

In our facility, anticoagulation was formerly administered using fraxiparin. For various reasons, in 2015, the preferred medication was switched to tinzaparin, which is made in Europe. Tinzaparin supplies therefore need to be relatively independent of local ASF outbreaks [6].

Coincidentally, we retrospectively analyzed patient data on prophylactic anticoagulation from 2012 to 2018 [10], dividing the AC-treated cohorts almost equally between fraxiparin and tinzaparin. We considered a heterogenous collective of patients with acute, malignant and benign disease as representative. In this study, we present data directly comparing tinzaparin and fraxiparin in prophylactic doses regarding adverse events such as rebleeding as well as post-operative hemorrhage and thromboembolic events (TE).

Methods

The study was approved by the ethics committee of the Medical Faculty, University of Leipzig (No. 053/19-ek).

Patient selection

517 patients undergoing brain tumor surgery (278 meningioma, 239 malignant brain tumors) and 297 suffering from SAH treated at the Department of Neurosurgery University Hospital Leipzig between 2012 and 2015 were included in this retrospective study). Selection was carried out via ICD-10 registration in the hospital database. Inclusion criteria were age above
18 years and conclusive documentation as well as prophylactic anticoagulation within 48 hours after operation or hospital admission.

**Diagnosis of adverse events**

Cranial computer tomography (CT) or Magnetic Resonance Imaging (MRI) scans were performed within 6 hours after the initial event and within 24 hours after surgery or intervention. Patients showing new neurological deficits or unsatisfactory wake-up reaction after intervention underwent CT scans.

Diagnostic methods (e.g. duplex sonography of the veins, CT scan of the chest or abdomen) for systemic ischemia were only performed if symptoms occurred.

**Anticoagulation protocol for SAH patients at our clinic**

Decisions on the type and dosage of anticoagulation were based on current guidelines [1, 2, 3] and interdisciplinary bedside rounds. LMWH doses were adjusted for body weight. The standard dosage was 4500 IE (tinzaparin) or 2850 IE (fraxiparin). Patients routinely received heparin within 48 hours. Reasons for no or delayed prophylactic AC were foudroyant rebleeding, death, or treatment with flow-diverting devices or a stent necessitating different AC. Moreover, patients suffering from acute, life-threatening embolisms such as pulmonary embolism were therapeutically anticoagulated immediately.

**Assessed data**

Biographic: Gender, age, BMI, smoking, preexisting hypertension, preexisting therapeutic anticoagulation

Primary endpoints: Intracranial rebleeding, ischemia (cerebral and systemic)

Comorbidities and complications: Dialysis, steroid medication, acute disorder of lungs or heart, coagulation disorder

**Statistical analysis**

To describe the cohort, nominal parameters are displayed as percentages.
The population was dichotomously classified depending on the occurrence or nonoccurrence of adverse events (intracranial rebleeding, systemic ischemia, and cerebral ischemia).

Dichotomous parameters were analyzed using the chi-squared test or Fisher’s exact test. Continuous data was analyzed with t-test, normality test was performed. P-values below 0.05 were considered statistically significant.

All analyses were computed using GraphPad QuickCalcs (www.graphpad.com), GRAPHPAD SOFTWARE, LLC, San Diego, USA, 2020.
Results

Table 1 Baseline data. Groups are comparable regarding demographic and medical data.

|                  | Fraxiparin (n = 398) | Tinzaparin (n = 416) | p-value (t-test / Fisher’s exact) |
|------------------|----------------------|----------------------|----------------------------------|
| Demographic      |                      |                      |                                  |
| Gender           | 167 M (42.0%)        | 182 M (43.8%)        | 0.6205                           |
|                  | 231 F (58.0%)        | 234 F (56.2%)        |                                  |
| Age (average in years) | 59 ± 15.0           | 60 ± 14.6            | 0.3354                           |
| BMI (Average)    | 26 ± 4.5             | 26 ± 4.6             | 1.000                            |
| Underlying disease |                     |                      |                                  |
| Malign brain tumor | 106 (26.6%)         | 133 (32.0%)          | 0.0906                           |
| Meningioma       | 149 (37.4%)          | 129 (31.0%)          | 0.0550                           |
| SAH              | 143 (35.9%)          | 154 (37.0%)          | 0.7710                           |
| Medical history  |                      |                      |                                  |
| Preexisting anticoagulation | 49 (12.3%)    | 55 (13.2%)           | 0.7530                           |
| Smoker           | 71 (17.8%)           | 80 (19.2%)           | 0.6523                           |
| Steroid medication | 196 (49.2%)         | 190 (45.7%)          | 0.3259                           |
| Coagulation disorder | 35 (8.8%)          | 34 (8.2%)            | 0.8018                           |

814 received prophylactic heparinization within 48 hours. Patients’ cohorts showed typical distribution of demographic data and preexisting medical conditions compared to typical cohorts of the specific disease. Cohorts showed no significant differences in baseline data. Patients with preexisting anticoagulation (n = 104, 12.8%) were not excluded from the cohorts. We performed subgroup analysis for patients with preexisting anticoagulation for meningioma, SAH and glioma individually. For meningioma and glioma surgery, therapeutic AC was paused for surgery. Logically, we found no effect on adverse events. In SAH however, preexisting anticoagulation prior to the initial event increased the risk of intracranial rebleeding (p = 0.009, OR 2.417, 95% CI of OR 1.278–4.570). This effect turned out to be insignificant when groups were combined. There was no difference between tinzaparin and fraxiparin groups (p = 0.7101).
Table 2 Adverse events of the entire cohort treated with prophylactic fraxiparin or tinzaparin. 814 patients received prophylactic anticoagulation.

| Adverse events combined (n = 814) | Fraxiparin (n = 398) | Tinzaparin (n = 416) | p-value |
|----------------------------------|---------------------|---------------------|---------|
|                                  | Chi-squared         | Fisher’s exact      |         |
| Rebleeding conservative (overall)| 35 (8.8%)           | 43 (10.3%)          | 0.4996  | 0.4757 |
| Rebleeding operative             | 13 (3.3%)           | 11 (2.6%)           | 0.7551  | 0.6818 |
| Thromboembolic event (overall)    | 22 (5.5%)           | 18 (4.3%)           | 0.5287  | 0.517  |
| Deep vein thrombosis             | 8 (2.0%)            | 4 (0.96%)           | 0.3513  | 0.2561 |
| Pulmonary embolism               | 9 (2.3%)            | 9 (2.2%)            | 0.9417  | 1      |
| Systemic thromboembolism         | 5 (1.3%)            | 5 (1.20%)           | 0.9568  | 1      |

814 patients were treated prophylactically with either fraxiparin (398) or tinzaparin (416).

Regarding hemorrhagic complications, we divided patients between those who did or did not undergo surgical treatment of rebleeding to gauge bleeding severity. The reasons for delayed or non-prophylactic treatment were severe rebleeding, acute pulmonary embolism, or securing aneurysm with a stent or flow-diverting devices, making therapeutic AC necessary. After combining the heterogenous groups of patients, differences between fraxiparin and tinzaparin were not significant. No differences were observed regarding the adverse events considered.

**Discussion**

Tinzaparin has been proven to be effective and safe in various patients [11, 12, 13]. Data on neurosurgical patients especially is scarce and does not compare specific substances, neither does it include different diseases [14, 15].

The study is limited due to its retrospective character. Although the number of examined patients is relatively high (n = 814), the study is not sufficiently powered to securely exclude differences between the substances investigated. Patient groups are heterogenous regarding underlying disease. Despite differences in underlying pathomechanism of rebleeding and
thromboembolism [16, 17], we assume the combined cohort applicable to heterogeneous neurosurgical patient collectives. When dividing into different subgroups regarding underlying disease, we did not find specific differences.

As AC is obligatory under current guidelines, we have no control group who is not treated with AC. For obvious reasons, we cannot draw any conclusions regarding the general safety or efficacy of prophylactic AC.

Conclusion

We suppose the application of tinzaparin in neurosurgical patients to be as safe as fraxiparin. According to our data, tinzaparin is a suitable alternative to other anticoagulative substances and so could be used to counter supply shortages.

References

1. Encke A, Haas S, Kopp I (2015) Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)-Ständige Kommission Leitlinien: S3-Leitlinie: Prophylaxe der venösen Thromboembolie (VTE). https://www.awmf.org/uploads/tx_szleitlinien/003-001l_S3_VTE-Prophylaxe_2015-12.pdf. Accessed Nov 8, 2019

2. Diringer MN, Bleck TP, Claude Hemphill J, Menon D, Shutter L, Vespa P, Bruder N, Connolly ES, Citerio G, Gress D, Hänggi D, Hoh BL, Lanzino G, Le Roux P, Rabinstein A, Schmutzhard E, Stocchetti N, Suarez JI, Treggiari M, Tseng M-Y, Vergouwen MDI, Wolf S, Zipfel G (2011) Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocritical care 15(2): 211–240

3. Faraoni D, Comes RF, Geerts W, Wiles, Matthew D. for the ESA VTE Guidelines Task Force (2018) European guidelines on perioperative venous thromboembolism prophylaxis: Neurosurgery. European Journal of Anaesthesiology 35(2): 90–95
4. Cote DJ, Smith TR (2016) Venous thromboembolism in brain tumor patients. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 25: 13–187.

5. Darkwah Oppong M, Buffen K, Pierscianek D, Herten A, Ahmadipour Y, Dammann P, Rauschenbach L, Forsting M, Sure U, Jabbarli R (2019) Secondary hemorrhagic complications in aneurysmal subarachnoid hemorrhage: when the impact hits hard. Journal of neurosurgery: 1–8

6. Khalidi A, Helo N, Schneck MJ, Origitano TC. Venous thromboembolism: deep venous thrombosis and pulmonary embolism in a neurosurgical population. J. Neurosurg. 2011;114:40–6. pmid:20815694

7. Rosovsky RP, Barra ME, Roberts RJ, et al. When Pigs Fly: A Multidisciplinary Approach to Navigating a Critical Heparin Shortage. Oncologist. 2020;25(4):334-347. doi:10.1634/theoncologist.2019-0910

8. https://www.sueddeutsche.de/wissen/afrikanische-schweinepest-kloeckner-ansteckung-1.5027058. Accessed Sep 10, 2020

9. https://www.reuters.com/article/us-germany-swinefever/germany-says-has-suspected-case-of-african-swine-fever-idUSKBN26033P. Accessed Sep 10, 2020

10. Wilhelmy F, Hantsche A, Wende T, Kasper J, Reuschel V, et al. (2020) Perioperative anticoagulation in patients with intracranial meningioma: No increased risk of intracranial hemorrhage?. PLOS ONE 15(9): e0238387.

11. Nutescu EA, Shapiro NL, Feinstein H, Rivers CW. Tinzaparin: considerations for use in clinical practice. Ann Pharmacother. 2003;37(12):1831-1840. doi:10.1345/aph.1D221

12. Marciniak CM, Kaplan J, Welty L, Chen D. Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy. PM R. 2012;4(1):11-17. doi:10.1016/j.pmrj.2011.10.007
13. Nelson-Piercy C, Powrie R, Borg JY, et al. Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. Eur J Obstet Gynecol Reprod Biol. 2011;159(2):293-299. doi:10.1016/j.ejogrb.2011.08.005

14. Chibbaro S, Tacconi L. Safety of deep venous thrombosis prophylaxis with low-molecular-weight heparin in brain surgery. Prospective study on 746 patients. Surg Neurol. 2008;70(2):117-121. doi:10.1016/j.surneu.2007.06.081

15. Pahatouridis D, Alexiou GA, Zigouris A, Mihos E, Drosos D, Voulgaris S. Coagulopathy in moderate head injury. The role of early administration of low molecular weight heparin. Brain Inj. 2010;24(10):1189-1192. doi:10.3109/02699052.2010.490510

16. Chen GR, Yao PS, Liu CB, et al. Risk factors of acute coagulation dysfunction after aneurysmal subarachnoid hemorrhage. Chin Neurosurg J. 2018;4:28. Published 2018 Oct 8. doi:10.1186/s41016-018-0135-6

17. Magnus N, D’Asti E, Garnier D, Meehan B, Rak J. Brain neoplasms and coagulation. Semin Thromb Hemost. 2013;39(8):881-895. doi:10.1055/s-0033-1357483